The first trial to report the antitumor activity of combination HIF-2α therapy was LITESPARK-003, a single-arm phase 2 study, that examined belzutifan plus cabozantinib in untreated (cohort 1) and previously treated advanced ccRCC (cohort 2). Here, EPAS1 is linked to nonpapillary renal cell carcinoma.